Innovations in pharmacy最新文献

{"title":"Socio Ecological Model (SEM) and Diffusion of Innovation (DOI) Integrated Framework: A Proposal for Integration to Improve Intervention in the Digital Age of Medicine.","authors":"Gousse Yolene, Joseph Ravenell, Robert Steptoe, Dawn Douglas, Joanne Camille, Chimene Castor","doi":"10.24926/iip.v15i4.6271","DOIUrl":"10.24926/iip.v15i4.6271","url":null,"abstract":"<p><p>Health promotion intervention theory must adapt as evidence grows to support the complexities of social and behavioral health fields. Following the COVID-19 pandemic, digital health continues to grow, requiring a re-evaluation of traditional models' applicability to these approaches. The authors propose adapting and integrating the Socio-Ecological Model (SEM) and Diffusion of Innovation (DOI) models for application with digital health to deliver interventions. We also describe the application of the SEM-DOI integration in conjunction with a demonstration project, a digital intervention to improve Metabolic Syndromes (MetS) health outcomes. Future health interventions may consider the proposed SEM-DOI model to account for individual and community-level factors during implementation and use as a guide for meaningful evaluation. Adaptations of theoretical models to current-state interventions and integration of multiple, established models are needed to sustain prevention efforts and efficacy over time.</p>","PeriodicalId":501014,"journal":{"name":"Innovations in pharmacy","volume":"15 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090095/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Implementation of a Targeted Technologic Screening Tool to Increase Pneumococcal Vaccine Uptake in Health-System Retail Pharmacies: A Quality Improvement Initiative.","authors":"Annika Skogg, Alicia L Zagel, R May O'Donnell, Ann M Philbrick, Mary R Nelson, Allyson Schlichte, Kassie A Klasen","doi":"10.24926/iip.v15i4.6345","DOIUrl":"10.24926/iip.v15i4.6345","url":null,"abstract":"<p><p><i>Background/Purpose:</i> Pneumococcal vaccination rates among eligible adults are lower than desired. Recently, pneumococcal vaccination guidelines for adults were updated to include new pneumococcal conjugate vaccines (PCV20), taking into consideration age, underlying risk factors, and previous vaccine status. To respond to PCV under-vaccination and help clarify the new guidelines, this project sought to develop a targeted pneumococcal vaccine screening tool and pop-up alert within retail pharmacies across a large health system with the goal of increasing rates of PCV20 vaccination. <i>Methods:</i> A Plan-Do-Study-Act (PDSA) cycle was employed to activate alerts within 24 retail pharmacies for patients indicated to be eligible for PCV20 vaccination. Adult patients who were PCV20 vaccine-naïve, met eligibility requirements, and were due for medication refill were identified through the electronic health record and uploaded to pharmacy software. Pharmacists screened patients for eligibility and inquired about willingness to receive PCV20 vaccine during the upcoming pharmacy visit. Vaccine rates and sociodemographic characteristics were compared before and after the PDSA cycle began, and reasons for patient decline were assessed. <i>Results:</i> Between December 2023 and April 2024, 1821 patients were screened for PCV20 vaccines, with 1369 (75%) patients eligible. Ultimately, 130 patients (9%) received PCV20 through the alert process, yet an additional 285 PCV20 vaccines were administered to additional patients, perhaps due to the intervention's success in promoting the tools such that pharmacists were more comfortable in screening patients for PCV20 vaccinations overall. Overall, the study represented a 140% increase in PCV20 vaccination rates compared to the same period of the previous year. The most common reason for declining vaccination was no interest in vaccines (n=231, 51%). <i>Conclusions:</i> This PDSA cycle demonstrated a vast increase in PCV20 vaccination rates in retail pharmacies across a large health system, indicating the potential utility of integrated technologic screening tools and alerts to increase administration of other routine immunizations.</p>","PeriodicalId":501014,"journal":{"name":"Innovations in pharmacy","volume":"15 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-12-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090080/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121935","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Perceptions of Biosimilars Among Healthcare Providers in Saudi Arabia.","authors":"Mohammed Al Qahtani, Ahmed Al-Jedai, Albert Wertheimer","doi":"10.24926/iip.v15i4.6371","DOIUrl":"10.24926/iip.v15i4.6371","url":null,"abstract":"<p><p><i>Background:</i> Biosimilars are safe and effective treatments for chronic diseases, including cancer and rheumatoid arthritis. The Saudi Food and Drug Authority (SFDA) oversees the quality and registration of biosimilars in Saudi Arabia. However, disparities among regulatory authorities such as the lack of guidelines for biosimilars in rheumatology affect healthcare providers' perceptions, leading to hesitancy in switching from reference products to biosimilars. This study aimed to explore the perceptions of Saudi healthcare professionals regarding biosimilars. <i>Methods:</i> A convenience sample of 87 participants (75 pharmacists and 12 physicians) was analyzed. The data were collected between December 2022 and February 2023. A logistic regression model was used to predict the intention toward biosimilars. <i>Results:</i> Years of practice among physicians significantly influenced their intention to prescribe biosimilars. Positive correlations were also observed between intentions towards prescription and beliefs regarding the safety and efficacy of biosimilars. Pharmacists' authority and knowledge of biosimilars correlated with their intention to substitute or dispense them. However, the logistic regression analysis indicated that behavioral, normative, and control beliefs were not significant predictors of the intention to prescribe or substitute biosimilars in either group. <i>Conclusions:</i> Highlighting the significance of continuing education and coordinating efforts in the international harmonization of biosimilar guidelines, as well as education for healthcare professionals, is required for addressing clinical concerns and enhancing confidence in biosimilars.</p>","PeriodicalId":501014,"journal":{"name":"Innovations in pharmacy","volume":"15 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090085/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121938","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Scopus Indexing Delays of Articles Published in Major Pharmacy Practice Journals.","authors":"Samuel O Adeosun","doi":"10.24926/iip.v15i4.6322","DOIUrl":"10.24926/iip.v15i4.6322","url":null,"abstract":"<p><p><i>Background</i>: Authors of bibliometric studies often wait for an arbitrarily prolonged period to allow for complete indexing of documents in the Scopus database after the end of the period to be studied (period-of-interest), thus negatively affecting recency (interval between publication date the date of the latest data reported) in bibliometric studies. <i>Objective</i>: The goal of this study is to determine the indexing delays in Scopus following online publication, to provide evidence-based recommendations for when data collection in Scopus should start after the end of the period-of-interest. <i>Methods</i>: Scopus indexing dates were prospectively collected for documents published in 2022 in 7 major pharmacy practice journals (aim 1). A time-to-event analysis was done on all documents published online from August to October 2022 (aim 2). Indexing delays and Kaplan-Meier curves of indexing delays were also compared between Scopus and PubMed using Wilcoxon signed-rank and Log-Rank tests, respectively. <i>Results</i>: All 7 journals (843 documents) and 4 journals (212 documents) were included in aims 1 and 2, respectively. Indexing delay was significantly longer in Scopus versus PubMed (median = 36 vs. 3 days). The Kaplan-Meier curves were also significantly different; with median survival time of indexing in Scopus and PubMed being 4 and 2 weeks, respectively. Notably, 91% of the subset studied have been indexed in Scopus (versus 97% in PubMed) by 10 weeks after online publication. <i>Conclusion</i>: Scopus indexing delays do not support the arbitrarily prolonged wait for bibliometric data to accumulate. A 10-week wait time provides a reasonable balance between the recency and completeness of published data. This evidence-based recommendation would improve recency without sacrificing data completeness in bibliometric studies.</p>","PeriodicalId":501014,"journal":{"name":"Innovations in pharmacy","volume":"15 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090081/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121940","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Appropriate Use of Inpatient Erythropoiesis Stimulating Agents.","authors":"Chenghao Cui, Timothy Nguyen, Mohammad A Rattu","doi":"10.24926/iip.v15i4.6284","DOIUrl":"10.24926/iip.v15i4.6284","url":null,"abstract":"<p><p><i>Background</i>: Anemia is a significant global public health issue, and is associated with lethargy, weakness, tiredness, and shortness of breath. Erythropoiesis stimulating agents (ESAs) are recombinant/synthetic erythropoietin and can increase hemoglobin (Hb) levels. There are increased risks of cardiovascular events and death associated with the use of ESAs when raising Hb levels above 12 g/dL. <i>Methods:</i> The objective was to assure safety and appropriate use of ESA. We performed a baseline assessment via a retrospective chart review, including patients who recently received an inpatient dose of an ESA within Mount Sinai Hospital (MSH) from November 1, 2015 (after MSH ESA guideline revision) to August 1, 2023. All adult patients who received an ESA (originator or biosimilar products) during hospitalization were included. Data collection was in reverse chronology, and the most recent dose administered to each unique patient was collected. <i>Results</i>: If an ESA dose was dispensed when the Hb was less than the upper limit of the target Hb for the specific indication, this was considered appropriate use. Based on data from June 15 to August 1, 2023 (~47 days of inpatient utilization), for the primary outcome, 169 out of 171 doses (98.8%) met the predefined criteria for appropriateness. One dose was dispensed when the Hb was 11.1 g/dL to a patient on renal replacement therapy, and one dose was dispensed when the Hb was 13.8 g/dL to a surgical patient who refused blood transfusions. Among secondary outcomes of interest, there was a difference in blood transfusions administered in critical versus non-critical care settings. <i>Conclusion</i>: Inpatient use of ESA at MSH was appropriate when looking at Hb targets. There are currently no formal order sets, service-line restrictions, or additional chairperson approvals needed at MSH. Despite this, there remained significant adherence to prevailing Hb targets, reflecting provider and pharmacy teams' knowledge and awareness of contemporary best practices.</p>","PeriodicalId":501014,"journal":{"name":"Innovations in pharmacy","volume":"15 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090088/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Yes, and…?: Reframing pharmacy faculty turnover as interconnectedness and relationality.","authors":"Sara A Thompson","doi":"10.24926/iip.v15i4.6149","DOIUrl":"10.24926/iip.v15i4.6149","url":null,"abstract":"","PeriodicalId":501014,"journal":{"name":"Innovations in pharmacy","volume":"15 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090082/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121679","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Astropharmacy: PAR Model and Space Pharmacy Council to Preparing Pharmacists for Space Missions.","authors":"Muhammad Ahmer Raza","doi":"10.24926/iip.v15i4.6385","DOIUrl":"10.24926/iip.v15i4.6385","url":null,"abstract":"","PeriodicalId":501014,"journal":{"name":"Innovations in pharmacy","volume":"15 4","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-11-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12090089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144121905","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Development, Pilot, and Evaluation of a Qualitative Documentation Tool for Pharmacists to Share High Impact Patient Intervention Stories.","authors":"Alex William Middendorf, Aaron Hunt, Alexa Vanden Hull, Deidra Van Gilder, Erin Miller, Sharrel Pinto","doi":"10.24926/iip.v15i3.5772","DOIUrl":"10.24926/iip.v15i3.5772","url":null,"abstract":"<p><p><i>Background:</i> Community pharmacists are often the most accessible member of the healthcare team to many patients and can play a key role in managing their chronic conditions, such as diabetes or heart disease, through enhanced pharmacy services. Despite their accessibility, pharmacy services are often underutilized due, in part, to a lack of adequate reimbursement models that comprehensively encapsulate all elements of those pharmacy services. While routine documentation of services does collect certain qualitative data, they do not always indicate the nuance of the full scope of services with resulting robust impact and value of those services for the patient and healthcare system. <i>Objective:</i> To develop and pilot an online reporting tool for pharmacist documentation of high impact patient intervention \"stories\" that includes the nuances of care provision processes in outpatient pharmacy settings that promote positive outcomes. <i>Methods:</i> An online Patient Stories Reporting Tool (PRST) was developed to allow outpatient pharmacists to document details on distinct direct patient care encounters, or \"stories\", that they felt showcased their value. Documentation through PSRT included limited quantitative data and qualitative data with a focus on a free response narrative for the \"story\". In a pilot, the PSRT was distributed to 18 pharmacists across 16 practice sites from one partnering pharmacy organization. Qualitative data, the focus of the included analysis, was collected, assessed by project team members, and organized by intervention types. <i>Results:</i> Forty-seven stories involving 17 pharmacists across 13 practice sites from August 2021 to March 2023 were reported. Three types of key intervention stories were identified including General Patient Education (7 stories), Medication Optimization (20 stories), and Cost Reduction (20 stories). Given the nature and scope of this initial pilot, one story for each of the three most prevalent intervention types was identified as exemplifying the types of stories the tool can collect and are subsequently discussed in detail. <i>Conclusions:</i> The three selected stories help to characterize the services pharmacists provide, the critical components of pharmacist-patient interactions, and the value of sharing these stories utilizing tools such as the PSRT. Through these stories, the PSRT also begins to record the nuances of pharmacist interventions and the impact they can make in a patient's healthcare journey. Potential applications of the tool are multivarious including supporting improvements in the perception of pharmacists' roles on the healthcare team and justifying expansion of reimbursement models.</p>","PeriodicalId":501014,"journal":{"name":"Innovations in pharmacy","volume":"15 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560001","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Incorporating Evidence-Based Teaching into Pharmacy Education: A Case Study on the Use of Educational Theory in the Backward Design of a Drug Information Course.","authors":"Christopher S Wisniewski, Jennifer N Wisniewski, Rachel Whitney, Emily P Jones","doi":"10.24926/iip.v15i3.5873","DOIUrl":"10.24926/iip.v15i3.5873","url":null,"abstract":"<p><p><i>Background:</i> One way to incorporate evidence-based teaching into healthcare education is through backward design, a pedagogical design process that starts with creating learning outcomes, then moves to assessments, followed by content creation. This study uses backward design as a framework to present an applied experience of evidence-based teaching in the design and refinement of an introductory drug information course presented in the first year of a traditional 4-year PharmD curriculum. <i>Case Description:</i> In addition to backward design, evidence-based teaching methods included scaffolding, pass-fail grading standards, formative assessments, flipped classroom, and gamification. Additionally, innovative assessment techniques and teaching activities were created. The full evolution of this course, along with student performance, student perceptions, faculty workload and faculty experience, are described. <i>Case Themes:</i> Overall, using evidence-based methodologies led to improved organization and enhanced faculty and student satisfaction. Data showed students performed well based on both assessment and course averages. Faculty workload was substantial during the initial development of the course and was mitigated once structure and organization had been better optimized over years of revision. <i>Impact:</i> This report provides a model for others to incorporate evidence-based teaching methods into course design in both incremental and large-scale changes. The incorporation of these ideas takes time and work from faculty but this effort has the potential to yield improved student learning and perception. Dedication to continuous review and revision of developed educational content is encouraged. Faculty found this experience rewarding and felt that it made them better and happier educators.</p>","PeriodicalId":501014,"journal":{"name":"Innovations in pharmacy","volume":"15 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and Predictors of Non-Benzodiazepine Use in Patients with Alcohol Withdrawal Syndrome in United States Emergency Departments - a cross-sectional study.","authors":"Kirolos Zakhary, Sophia Bruno, Caleb A Myatt, Vindya Perera, Kerolese Saleh, Jacob A Smearman, Madeline M Yuzwa, Mate M Soric, Stephanie Zampino","doi":"10.24926/iip.v15i3.6270","DOIUrl":"10.24926/iip.v15i3.6270","url":null,"abstract":"<p><p><i>Purpose:</i> Benzodiazepines are the mainstay treatment in Alcohol Withdrawal Syndrome (AWS), though they have the potential for abuse and cognitive side effects. Non-benzodiazepines are of growing interest for treatment of AWS; however, the prevalence of non-benzodiazepine use remains unknown. The purpose of this study is to evaluate the prevalence and predictors of non-benzodiazepine use for AWS in the Emergency Department (ED). <i>Methods:</i> A cross-sectional, retrospective study utilizing data from the National Hospital Ambulatory Medical Care Survey (NHAMCS) spanning the years 2014-2020 investigated patients presenting to the ED with AWS. The primary outcome of this study is the prevalence of patients with AWS who received non-benzodiazepine treatment during their ED visit. The secondary outcome was the identification of predictor variables for non-benzodiazepine use. A multivariate logistic regression with a backward elimination approach was employed to identify predictor variables. <i>Results:</i> A total of 2,300 unweighted ED visits included over the study years. When weighted, this represented over 15.2 million ED visits. Across the study period, 3.1% (95% CI, 1.6-6.1%) of patients received non-benzodiazepines. Positive predictors of non-benzodiazepine use included the year 2020 compared to 2014 (OR 6.32, 95% CI, 1.39-28.73) and comorbid depression (OR 4.13, 95% CI, 1.38-12.36). Negative predictors of non-benzodiazepine use included ages 18-40 compared to ages 41-64 (OR 0.34, 95% CI, 0.13-0.91), nursing home residence compared to private residence (OR 0.02, 95% CI, 0.001-0.80), and the South compared to the Midwest region of the United States (OR 0.19, 95% CI, 0.07- 0.51). <i>Conclusion:</i> This study found that non-benzodiazepine use, despite being less common, is becoming more prevalent. Further research is needed to determine the optimal dosing and duration of non-benzodiazepines for AWS. Understanding the factors influencing the prescription patterns of non-benzodiazepines can contribute to informed decision-making and improve the management of AWS.</p>","PeriodicalId":501014,"journal":{"name":"Innovations in pharmacy","volume":"15 3","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11524209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142560005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}